Meeting Goals/Purpose

This Symposium is designed to provide state-of-the-art information on the experimental biology, etiology, prevention, diagnosis, and therapy of breast cancer and premalignant breast disease to an international audience of academic and private physicians and researchers.

The scientific program consists of formal lectures by experts in clinical, translational, and basic research, selected slide and poster presentations, forums and case discussions. The official language of the symposium is English. Simultaneous translation is not provided.

Target Audience

This international symposium is directed primarily towards academic and private physicians and researchers involved in breast cancer in medical, surgical, gynecologic, and radiation oncology, as well as patient advocates and other appropriate health care professionals. We anticipate 10,000+ attendees from more than 102 countries.

Meeting Location

We are very pleased to announce that the San Antonio Breast Cancer Symposium^® will take place in 2024. The Symposium offers attendees the unique opportunity to participate in person in San Antonio, Texas or virtually. The dates will be December 10-13, at the Henry B. Gonzalez Convention Center, 900 E. Market Street, San Antonio, TX 78205 USA.

Program

The Symposium program is nearly complete. Visit the Program page to see the current list of confirmed speakers.

Executive Committee

Carlos L. Arteaga, MD, UT Southwestern, Harold C. Simmons Cancer Center, Dallas, TX, Co-Director
Virginia G. Kaklamani, MD, UT Health San Antonio Mays Cancer Center, San Antonio, TX, Co-Director
Margaret Foti, PhD, MD (hc), American Association for Cancer Research, Philadelphia, PA
Kate Lathrop, MD, UT Health San Antonio Mays Cancer Center, San Antonio, TX (ex-officio)
Dean Post, American Association for Cancer Research, Philadelphia, PA (ex-officio)
Charles M. Perou, PhD, University of North Carolina, Chapel Hill, NC
David Gius, MD, UT Health San Antonio Mays Cancer Center, San Antonio, TX
Mark Bonnen, MD, UT Health San Antonio Mays Cancer Center, San Antonio, TX
Reuben Harris, PhD, UT Health Mays Cancer Center, San Antonio, TX
Alana Welm, PhD, University of Utah Huntsman Comprehensive Cancer Center, Salt Lake City, UT

Program Planning Committee

Christine Ambrosone, PhD, Roswell Park Comprehensive Cancer Center, Buffalo, NY
Carey Anders, Duke Cancer Institute, Durham, NC
Justin Balko, PhD, Vanderbilt University, Nashville, TN
Thelma Brown, University of Alabama at Birmingham, Birmingham, AL
David Cescon, MD, PhD, Princess Margaret Cancer Centre, Toronto, Canada
Suzanne Conzen, MD, UT Southwestern Medical Center, Dallas, TX
Christine Desmedt, PhD, Katholieke Universiteit Leuven, Leuven, Belgium
Carol Fabian, MD, University of Kansas Medical Center, Kansas City, KS
Heide Ford, PhD, University of Colorado, Denver, CO
Fred Howard, MD, University of Chicago, Chicago, IL
Sara Hurvitz, MD, University of Washington Fred Hutchinson Cancer Center, Seattle, WA
Tari A. King, MD, FACS, Brigham and Women's Hospital, Boston, MA
Adrian Lee, PhD, Institute for Precision Medicine, Pittsburgh, PA
Sherene Loi, PhD, Peter MacCallum Cancer Centre, Melbourne, Australia
Julia Maues, GRASP, Washington, DC
Heather McArthur, MD, MPH, UT Southwestern Medical Center, Dallas, TX
Debra Patt, MD, PhD, MBA, Texas Oncology, Austin, TX
David Rimm, MD, PhD, Yale School of Medicine, New Haven, CT
Christos Sotiriou, MD, PhD, Jules Bordet Institute, Anderlecht, Belgium
Antoinette Tan, MD, MHSc, FACP, Atrium Health Levine Cancer Institute, Charlotte, NC
Neil Vasan, MD, PhD, Columbia University Irving Medical Center, New York, NY
Adrienne Waks, MD, Dana-Farber Cancer Institute, Boston, MA
Antonio Wolff, MD, Johns Hopkins University, Baltimore, MD
Richard Zellars, MD, Indiana University School of Medicine, Indianapolis, IN

Financial Disclosure Information

As an ACCME-accredited CME provider, UT Health Science Center San Antonio^® must ensure that its CME activities are independent of the control of commercial interests. All speakers and planning committee members for the UT Health Science Center San Antonio sponsored programs are expected to disclose (prior to the activity) all “financial relationships” in any amount occurring within the past 24 months. Disclosures are then reviewed to identify any "relevant" financial relationships that create a conflict of interest. (“Relevant” financial interest or other relationships can include such things as grant or research support, employees, consultants, major stockholders, members of speaker bureau, etc.)

The UT Health Science Center San Antonio and a planner of SABCS^® 2024 with no financial relationships with ineligible companies will review all financial disclosure information for all speakers, facilitators, and planning committee members; and determine and resolve all conflicts of interests.

All financial relationships have been reviewed and mitigated.

Advocate Financial Assistance

Patient advocates wishing to apply for financial assistance for the 2024 SABCS^® should contact the Alamo Breast Cancer Foundation for information and an application. Applications are available online. Please see their website for more information and qualifications.

Email: info@alamobreastcancer.org

Web: www.alamobreastcancer.org